Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7057MR)

This product GTTS-WQ7057MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Age-related macular degeneration (AMD), Diabetic retinopathy research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ7057MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6165MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CP-751871
GTTS-WQ8631MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ820MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-085
GTTS-WQ11534MR IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MGA031
GTTS-WQ2737MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG-139
GTTS-WQ3962MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ3432MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AV-299
GTTS-WQ1705MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA aDabi-Fab
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW